Innovation shapes the future
Cancer immunotherapy based
on viral vectors
on viral vectors
Explore our platform
We combine the use of viral vectors that have been engineered and optimized to express artificial genes encoding high-dimensional strings of human neoantigens, with state-of-the art bioinformatics for cancer neoantigen prediction. The unprecedented neoantigen-encoding capacity of our platform and its ability to efficiently and consistently express large numbers of neoantigens, provides significant advantages over other strategies, offering a unique approach to the potentiation of human anti-tumor responses.
An off-the-shelf cancer immunotherapy for dMMR/MSI tumors
Tumors associated with Mismatch Repair Deficiency (dMMR) and Microsatellite instability (MSI) accumulate insertion/deletion mutations (indels) that are predictable as they principally arise at mononucleotide repeats. These indel mutations in coding regions result in a translational shift that generate frame shift peptides (FSPs). FSPs are highly immunogenic and may be safely utilized in vaccines as they bear no resemblance to natural protein sequences found in the human proteome. As such, they are ideal tumor-specific neoantigens.
As these mutations are targeted to a limited number of genes across the genome, several of them are shared across different patients. MSI-associated tumors consequently offer a unique opportunity for an ‘off-the-shelf’ vaccine.
NOUS-209 encodes 209 unique FSP cancer neoantigens found in different MSI tumor types (Leoni et al, 2020).
The NOUS-209 open label Phase 1b trial is evaluating the safety, feasibility, and preliminary efficacy per RESIST 1.1 criteria of NOUS-209 in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab in 21 patients. The recommended Phase 2 dose (RP2D) of NOUS-209 has been declared and enrollment in the Phase Ib dose expansion phase of the clinical trial is ongoing across multiple US sites (NCT04041310).
Personalised cancer vaccine
NOUS-PEV is a personalised cancer vaccine based on patient-specific neoantigens sourced from individual patient tumor mutanomes. The technology may be applied to any cancer indication where a tumor biopsy is available that is suitable for next-generation sequencing (NGS).
Nouscom has developed a robust and rapid manufacturing process from patient biopsy to vaccine release. This process allows for the assembly of strings of up to 60 unique patient mutanome-specific neoantigens within a single vector and the production of small patient-specific quantities of personalized vaccine.
In March 2021, Nouscom received regulatory approval to initiate a multicenter Phase 1b trial of NOUS-PEV and will be enrolling patients in Spain and other European countries. The trial will evaluate, feasibility and preliminary efficacy per RESIST 1.1 criteria of NOUS-PEV in combination with the anti-PD-1 checkpoint inhibitor in 28 patients with either locally advanced 1L melanoma or 1L NSCLC expressing more than 50% PD-L1.